The www.biotechvortex.com section of the site I started when I started seeing the connections, links, partnerships, new technologies and mergers that were taking place in the biotech sector. Thank you for visiting. Vortexes are powerful and transformational centers of energy.
A BIOTECH VORTEX™ is occurring across the entire healthcare sector as companies are now Seeking Biotech Partnerships to gain momentum.
Biotech & Biotech Partnerships.
Biotech & Medtech Partnerships.
Biotech & Medtech & Medical
Biotech & Health Systems Partnerships.
September 26, 2019 at 8:00 AM EDTPDF Version
Collaboration seeks to explore fundamental immunological processes and identify potential therapeutic opportunities
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 26, 2019-- Moderna, Inc., (Nasdaq: MRNA)
September 26, 2019
Cambridge, Mass. - September 26, 2019 — Harvard University
Wed November 20, 2019 8:00 AM|PR Newswire|About: ABBV
Dragonfly will use its TriNKET™ platform to develop drug candidates directed to multiple targets for autoimmune disorders, and oncology. AbbVie receives exclusive options to license a number of Dragonfly's natural killer (NK) cell engager immunotherapies.
WALTHAM, Mass., Nov. 20, 2019 /PRNewswire/ -- Dragonfly Therapeutics
Fri November 15, 2019 9:00 AM|Business Wire|About: PFE
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- The Bristol-Myers Squibb-Pfizer Alliance
Agreement Contingent on FTC Consent Decree and Closing of Pending Bristol-Myers Squibb-Celgene Merger
Pending Bristol-Myers Squibb-Celgene Merger Expected to Close by End of 2019
NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (BMY) announced today that Celgene Corporation (CELG), in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement with Amgen (AMGN) under which Amgen would acquire the global rights to OTEZLA® (apremilast) for $13.4 billion in cash.
Mon November 18, 2019 6:00 AM|Business Wire|About: DRNA
– Collaboration to Explore Liver Cell Targets Using Dicerna’s GalXC™ Technology With the Potential to Deliver a Significant Number of Clinical Candidates –
– Each Company to Retain Rights to Co-Develop and
Co-Commercialize Product Candidates –
– Dicerna to Receive Upfront Payment of USD 175 Million and
Equity Investment of USD 50 Million –
– Dicerna is Eligible to Receive an Additional USD 75 Million Over the First Three Years, Plus Up to USD 357.5 Million per Target in Potential Milestone Payments, and Royalties on Product Sales –
– Dicerna to Host Conference Call Today at 8:00 a.m. ET –
Mon November 18, 2019 7:00 AM|GlobeNewswire|About: MTEM
-Molecular Templates (MTEM) to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales-
BOSTON and AUSTIN, Texas, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular Templates, Inc.
Mon November 18, 2019 8:15 AM|PR Newswire|About: VAR
PALO ALTO, Calif., Nov. 18, 2019 /PRNewswire/ -- Varian (VSEA) (NYSE: VAR)
Sat November 16, 2019 10:45 AM|Business Wire|About: MDCO
- Inclisiran achieved 58% LDL-C lowering with time-adjusted reductions of 56% sustained over 18 months of treatment in patients with atherosclerotic cardiovascular disease (ASCVD)
- ORION-10 study affirmed inclisiran’s excellent safety profile, including no treatment-related liver or renal abnormalities
- Results presented today during late-breaking science session at American Heart Association annual meeting in Philadelphia
- The Medicines Company (MDCO) to host investor conference call and webcast on Monday, November 18, 12:00 pm EST
Tue November 12, 2019 7:00 AM|GlobeNewswire|About: EDIT
The companies will continue to collaborate to discover and develop the next generation of engineered alpha-beta T cells
Editas Medicine (EDIT) to receive a $70 million payment and may be eligible for future milestone and royalty payments
CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc., a leading genome editing company, today announced an amended collaboration with Celgene Corporation (Nasdaq: CELG)
Tue November 12, 2019 8:02 AM|Business Wire|About: EXEL
– Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial –
Tue November 12, 2019 9:00 AM|PR Newswire|About: CELG
Celgene to receive exclusive options to license a number of Skyhawk's product candidates directed to multiple high-value autoimmune disorder, oncology, and immuno-oncology targets.
Skyhawk to receive $80 Million upfront payment and is eligible for potential milestone payments and royalties.
WALTHAM, Mass., Nov. 12, 2019 /PRNewswire/ -- Skyhawk Therapeutics, Inc. (Skyhawk) today announced that it has entered into a second global strategic collaboration with an affiliate of Celgene Corporation (CELG)
- Exicure (XCUR) to Receive $25 Million Upfront Payment and Up to $725 Million in potential Milestones
- Exicure to Host Conference Call Today at 8:30am ET/7:30am CT
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc., (NASDAQ:XCUR)
Allergan is focused on driving innovation in four core therapeutic areas. As part of our approach to delivering innovation for better patient care, we have built one of the broadest pharmaceutical and device research and development pipelines in the industry.
Thu November 14, 2019 8:30 AM|GlobeNewswire|About: SRPT
CAMBRIDGE, Mass. and RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (SRPT),
Thu November 14, 2019 9:00 AM|GlobeNewswire|About: ARNA
NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE)
PUBLISHED6 November 2019
Wed November 6, 2019 7:30 AM|GlobeNewswire|About: BIIB
CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (BIIB) today announced a new proposed transaction with Samsung Bioepis Co., Ltd.
SHANGHAI and LONDON, Nov. 6, 2019 /PRNewswire/ -- Antengene Corporation today announced that it has entered into a licensing agreement with AstraZeneca (AZNCF) (LSE/STO/NYSE: AZN)
Fri November 8, 2019 5:59 PM|PR Newswire|About: NVTA
Fri November 8, 2019 4:05 PM|GlobeNewswire|About: ADROQ3: 11-07-19 Earnings SummaryEPS of $-0.26 misses by $-0.02 Revenue of $4.8M (56.68% Y/Y) beats by $0.76M
BERKELEY, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,
(see www.clinicaltrials.gov, identifier NCT03396445).
Mon November 11, 2019 9:47 AM|GlobeNewswire|About: GALT
NORCROSS, Ga., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Today, Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, announced a collaboration agreement with Siemens Healthineers, a global leader in medical technology, in nonalcoholic steatohepatitis (NASH) and liver fibrosis.
• Companies to Collaborate on the Commercialization of XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) in China
• Companies to Jointly Develop 20 Amgen (AMGN) Oncology Pipeline Assets, with BeiGene Responsible for Development and Commercialization in China as Part of the Global Development Plan
• Amgen to Purchase Approximately $2.7 Billion of BeiGene Shares
• BeiGene to Hold Analyst and Investor Call on Thursday, October 31 at 8:00 p.m. ET
CAMBRIDGE, Mass. and BEIJING, China, Oct. 31, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (BGNE) and Amgen
Nov. 11, 2019 1:30 PM ET | About: Amgen Inc. (AMGN)
Fri November 1, 2019 4:01 PM|GlobeNewswire|About: GLPG
Mechelen, Belgium; 1 November 2019; 21:01 CET – Gilead Therapeutics A1 Unlimited Company, an affiliate of Gilead Sciences, Inc. (NASDAQ: GILD), delivered an exercise notice to Galapagos NV (GLPGF) (Euronext & NASDAQ: GLPG)
Tue November 5, 2019 7:00 AM|Business Wire|About: TAK
− Ongoing Phase 1/2a Study of CD19 CAR-NK with Pivotal Study Expected to Enroll Patients in 2021
− Potential to be the First CAR Cell Therapy Approved for Outpatient Administration
TARRYTOWN, N.Y., Nov. 5, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
Tue October 22, 2019 9:00 AM|Business Wire|About: WBA
$25M, multi-year commitment builds on Walgreens (WBA) efforts to improve the health and well-being of people living with cancer nationwide
DEERFIELD, Ill. & DALLAS & RYE BROOK, N.Y.--(BUSINESS WIRE)-- Walgreens announced today a new collaboration with Susan G. Komen and The Leukemia & Lymphoma Society
Mon October 21, 2019 9:00 AM|PR Newswire|About: ABT PR Newswire
ABBOTT PARK, Ill., Oct. 21, 2019 /PRNewswire/ -- Abbott (ABT)
Tue October 22, 2019 1:00 AM|Business Wire|About: TAK
− Late-breaking data presented from a Phase 2a trial at UEG Week 2019, Barcelona, Spain, highlights potential of investigational medicine to prevent gluten induced immune activation in patients with celiac disease
− Takeda (TKPHF) acquires exclusive global license to investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle designed to induce tolerance to gluten in patients with celiac disease
OSAKA, Japan & CHICAGO--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and COUR Pharmaceutical Development Company, Inc. (“COUR”)
Tue October 29, 2019 5:05 PM|Business Wire|About: QGEN
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (QGEN)
Thu October 24, 2019 8:00 AM|PR Newswire|About: ABBV
NORTH CHICAGO, Ill., Oct. 24, 2019 /PRNewswire/ -- AbbVie (ABBV)
Wed October 30, 2019 6:59 AM|Business Wire|About: BMY
Partnership to accelerate the adoption of next-generation sequencing (NGS) in clinical decision-making
October 1, 2019 | Microsoft News Center
Basel, and Redmond, October 1, 2019
Tue October 8, 2019 10:00 AM|GlobeNewswire|About: MDTGlobeNewswire
DUBLIN, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT)
Wed October 9, 2019 8:00 AM|Business Wire|About: BLUE
CAMBRIDGE, Mass. and BAGSVÆRD, Denmark--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) and Novo Nordisk A/S (NVO)
INDIANAPOLIS, Oct. 14, 2019 /PRNewswire/ -- Roche (ROCM) (SIX: RO, ROG; OTCQX: RHHBY)
Wed August 21, 2019 10:00 AM|Business Wire|About: PFE
NEW YORK--(BUSINESS WIRE)-- Pfizer (PFE)
Aug 28, 2019 | News, USA
Houston, Texas and Tuebingen, Germany, August 28, 2019 – Immatics Biotechnologies GmbH
Tue August 27, 2019 8:00 AM|PR Newswire|About: BMY
SEATTLE, Aug. 27, 2019 /PRNewswire/ -- Presage Biosciences
Mon September 16, 2019 3:00 AM|GlobeNewswire|About: MDTGlobeNewswire
- Eidos grants Alexion (ALXN) exclusive license to develop and commercialize AG10 in Japan -
- Phase 3 study of AG10 in ATTR cardiomyopathy underway in U.S. & Europe; Phase 3 trial in ATTR polyneuropathy planned to initiate in second half of 2019 -
- Agreement expands Alexion’s amyloidosis portfolio -
- Eidos to receive upfront payment of $25 million and equity investment of $25 million, with potential for additional Japanese-based milestone- & royalty-dependent payments -
ABBOTT AND SANOFI PARTNER TO INTEGRATE GLUCOSE SENSING AND INSULIN DELIVERY TECHNOLOGIES TO HELP CHANGE THE WAY DIABETES IS MANAGED
- Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin
- Two world leaders in diabetes work together to drive meaningful change in care
ABBOTT PARK, Ill. and PARIS, Sept. 16, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) and Sanofi
Pfizer has IDA-supported facilities at five sites in Ireland that employ 3,500 people. It is the largest pharmaceutical sector investor and employer. From an initial investment of €10 million in 1969, Pfizer's total investment in Ireland now stands at nearly €8 billion.
GSK employs 1,450 people in Ireland and first established operations here in 1975. It has two manufacturing operations in Dungarvan and is the largest employer in the town with almost 700 staff; it has a third manufacturing operation, where it develops and produces a range of bulk pharmaceuticals, together with R&D and European Trading operations in Cork; and in Dublin there are Sales and Marketing functions.
In 1997, Takeda, the largest pharmaceutical company in Japan, established a Formulation Plant in Bray, Wicklow, for the manufacture of three of the company’s blockbuster drugs (Prevacid, Blopress and Actos). The establishment of this facility was paramount to Takeda’s strategy in responding to expanding growth in the European and US markets. This plant has significantly expanded its operation since inception and operates on a 24 hour/7 day basis.
Merck & Co., New Jersey is a global research-driven pharmaceutical company and is the fifth largest pharmaceutical company in the world. Outside North America it is known as MSD.
INDIANAPOLIS, Aug. 8, 2019 /PRNewswire/ -- Initial results from a feasibility study conducted by Eli Lilly and Company (NYSE: LLY), Evidation Health, and Apple Inc. (NASDAQ: AAPL)
Fri August 9, 2019 8:30 AM|Business Wire|About: GILD
-- Biktarvy demonstrated high efficacy and a high barrier to resistance in clinical trials through 48 weeks --
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD)
Thu August 15, 2019 8:00 AM|Canada Newswire|About: GILD
MISSISSAUGA, ON, Aug. 15, 2019 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada)
In-licensing: through in-licensing partnerships with global biotech partners, including MorphoSys, Genexine, MacroGenics and Ferring, we have quickly built our China Portfolio by acquiring multiple innovative clinical stage assets with favorable clinical safety and early efficacy data. In that respect, we are often considered an ideal China partner by our global partners because of our strong development capabilities and proven track record.
Out-licensing: the out-licensing deals enable us to streamline our pipeline and focus our resources on the most valuable assets. In addition, we seek co-development opportunities to share development costs and risks and territorial commercial rights with our partners. In the past two years, we have out-licensed three de-prioritized assets and initiated four co-development programs with partners such as ABL Bio, Everest Medicines and WuXi Biologics. The revenue we generated from out-licensing and co-development deals is expected to continue to grow as our pipeline progresses.
Our headquarters is based in Zhangjiang, Pudong, Shanghai. The Shanghai site has a state-of-the-art laboratory facility that hosts both our discovery unit and the CMC research unit (cell line and analytical development). There are also large open-office spaces hosting the R&D organization, the CMC department and the operation teams. Site address: Suites 802, 505, 702, West Tower, 88 Shangke Road, Pudong New District, Shanghai, China.
Copyright I-MAB Biopharma Co., Ltd. all rights reserved 2019
Switzerland is the world’s most-innovative country followed by Sweden, the United States of America (U.S.), the Netherlands and the United Kingdom (U.K.), according to the 2019 edition of the Global Innovation Index (GII), which also identifies regional leaders India, South Africa, Chile, Israel and Singapore, with China, Vietnam and Rwanda topping their income groups.
Switzerland is the world’s most innovative country followed by Sweden, the United States of America (U.S.), the Netherlands and the United Kingdom (U.K.), according to the GII 2019. https://www.wipo.int/global_innovation_index/en/2019/index.html
Karolinska University Hospital Solna Delivers HDR Brachytherapy Cancer Treatments with Varian Bravos Afterloader System
Thu July 25, 2019 3:00 AM|PR Newswire|About: VAR
NEWS PROVIDED BY Varian Jul 25, 2019, 03:00 ET
PALO ALTO, Calif. and STOCKHOLM, July 25, 2019 /PRNewswire/ -- Varian (NYSE: VAR) announced that the Karolinska University Hospital Solna in Sweden is the first hospital in Scandinavia to deliver High Dose Rate (HDR) brachytherapy treatments using the new Bravos™ afterloader system
Karolinska University Hospital is one of Europe’s premier health facilities. Together with the world-respected Karolinska Institutet, we lead in development and medical break-throughs.
In 2018, the Asia-Pacific health tech industry had a record-breaking year in total funding, closing at $6.3 billion, making the Asia-Pacific health tech ecosystem the second largest in the world in value, behind only the United States. As the health tech boom surges in the Asia-Pacific, healthcare solutions geared towards medical diagnosis, health management, patient solutions, and population health management garnered multimillion-dollar deals.
Health tech may hold the promise of providing new inroads for the biggest healthcare challenges of our time. From patient care, to data management, personalized medicine and population health, Smart Healthcare tools including blockchain, AI, 3D printing, and wearables, may be the key that unlocks new advances that make a meaningful difference for people around the globe.
That’s why Johnson & Johnson Innovation - JLABS (JLABS) in collaboration with Seoul Metropolitan Government (SMG), Korea Health Industry Development Institute (KHIDI), Janssen Korea Ltd. are launching the Seoul Innovation QuickFire Challenge in Smart Healthcare. Up to two innovators with the best idea, technology, or solution that aims to address a health need for the world's population will receive up to KRW150,000,000 (approximately US$134,000) in grant funding, entrance to the Seoul Bio Hub, and mentorship from experts at the Johnson & Johnson Family of Companies.
Up to KRW 150,000,000 (~ US $134,000)
Johnson & Johnson 2019 Q2 - Results - Earnings Call Slides
Jul. 16, 2019 9:35 AM ET Johnson & Johnson (JNJ)
The world’s largest JLABS and the first in Asia Pacific aims to support more than 50 life science start-ups from around the world with the hope to accelerate healthcare innovation in China and globally
SHANGHAI, June 27, 2019 — Johnson & Johnson Innovation, Division of Johnson & Johnson (China) Investment Ltd.
Bristol-Myers Squibb and Tsinghua University Announce Collaboration to Accelerate Early Research into Potential Therapies for Autoimmune Diseases and Cancer
AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology
Johnson & Johnson and Boston University Announce a New Alliance Focused on Tackling Lung Cancer
Shanghai Lung Cancer Innovation QuickFire Challenge
"partnerships help foster a culture of entrepreneurship and innovation in the university community.”.
Bill Nygren Comments on Bristol-Myers Squibb = "The company’s two most valuable drugs Opdivo and Yervoy should continue to grow revenue as they maintain effectiveness with new tumor types. Bristol Myers Squibb also has the most new molecular agents and the highest number of combinations of agents in trials. Moreover, the company’s R&D and marketing prowess also make it a desired partner for promising academic and small biotech innovators.
Bill Nygren - Oakmark Fund manager - invested in 6.5 million shares of Bristol-Myers Squibb for an average price of $54.03 per share. The manager dedicated 1.85% of his equity portfolio to the position.
Ray Dalio - Bridgewater Associates also invested in Bristol-Myers during the quarter.
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Jeff Auxier comments on Merck = Merck beat estimates in the second quarter of 2018 with $10.5 billion in revenues and EPS of $1.06. They were buoyed in the quarter by their signature cancer drug KEYTRUDA which allows the body’s immune system to destroy cancerous cells by blocking a protective enzyme in cancer cells. Sales grew 89% in the quarter to $1.667 billion and are expected to continue to grow to upwards of $13 billion annually by 2026. Recently KEYTRUDA was approved in China and the EU for metastatic melanoma.
Jeff Auxier Comments on Biogen = Biogen saw revenues increase by 9% to $3.4 billion. Revenue growth was driven by Spinal Muscular Atrophy drug Spinraza which saw a 108% increase in revenue. Spinraza is Biogen’s fastest growing drug which they hope will be able to offset the slowing Multiple Sclerosis product line. Biogen presented the detailed results for the phase II trials of their Alzheimer’s drug BAN2401 on July 25th. The results of the trial were positive with tested patients showing 30% less cognitive decline over 18 months than those who received the placebo, but the presentation garnered a mixed reception and caused Biogen’s stock to fall 9% in after-hours trading. Earlier in July, Biogen announced that the trials of the drug were looking very positive without giving any details, and this announcement may have caused many to anticipate that the results would be better than what was ultimately shown. Currently, Biogen’s stock is hurting from the results announcement, but their outlook is still positive in the long-run due to the strength of their pipeline. Another Alzheimer’s drug in Biogen’s pipeline, Aducanumab, just finished its enrollment for two phase III trials. This drug has been regarded as more promising than BAN2401, and if it is successful Biogen will have the only drug in a $12 billion market.
THOUSAND OAKS, Calif., July 31, 2018 /PRNewswire/ -Amgen (AMGN) announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus. The new plant is the first-of-its-kind in the U.S. and will use Amgen's proven next-generation biomanufacturing capabilities to manufacture products for the U.S.and global markets.